References
- 1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. DOI: 10.5114/pg.2018.8107210.5114/pg.2018.81072679113431616522
- 2. Campos FG. Colorectal cancer in young adults: A difficult challenge. World J Gastroenterol. 2017;23(28):5041-5044. DOI: 10.3748/wjg.v23. i28.504110.3748/wjg.v23.i28.5041
- 3. Connell LC, Mota JM, Braghiroli MI, Hoff PM. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment. Curr Treat Options Oncol. 2017;18(4):23. DOI: 10.1007/s11864-017-0463-310.1007/s11864-017-0463-328391421
- 4. Mármol I, Sánchez-de-Diego C, Pradilla DA, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197. DOI: 10.3390/ ijms1801019710.3390/ijms18010197529782828106826
- 5. Recio-Boiles A, Cagir B. Colon Cancer. [Updated 2021 Jan 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470380/
- 6. Maffeis V, NicolèL, Cappellesso R. RAS, cellular plasticity, and tumor budding in colorectal cancer. FronOncol. 2019;9;1255. DOI: 10.3389/fonc.2019.0125510.3389/fonc.2019.01255687775331803624
- 7. Buday L, Downward J. Many faces of Ras activation. Biochimica et Biophysica Acta. 2008;1786(2):178-87. DOI: 10.1016/j.bbcan.2008.05.00110.1016/j.bbcan.2008.05.00118541156
- 8. Takács T, Kudlik G, Kurilla A, Szeder B, Buday L, Vas V. The effects of mutant Ras proteins on the cell signalome. Cancer Metastasis Rev. 2020;39:1051-65. DOI: 10.1007/s10555-020-09912-810.1007/s10555-020-09912-8768033732648136
- 9. Hwang K, Yoon JH, Lee JH, Lee S. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers Biomedicines. 2021; 9(1):39. DOI: 10.3390/biomedicines901003910.3390/biomedicines9010039782481633466394
- 10. Porebska I, Harlozińska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21(2):105-15. DOI: 10.1159/00003011610.1159/00003011610686540
- 11. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: Monoclonal antibodies versus tyro-sine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007;62:53-61. DOI: 10.1016/j. critrevonc.2006.12.00810.1016/j.critrevonc.2006.12.008
- 12. Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. J Exp Clin Cancer Res. 2018;37(1):57. DOI: 10.1186/s13046-018-0719-110.1186/s13046-018-0719-1585091329534749
- 13. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemo-therapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304(16):1812-20. DOI: 10.1001/jama.2010.153510.1001/jama.2010.153520978259
- 14. BankovicLazarević D, Krivokapić Z, Barišić G, Jovanović V, Ilić D, Veljković M. Organized colorectal cancer screening in Serbia - the first round within 2013-2014. Vojnosanit Pregl. 2016;73:360-7. DOI: 10.2298/ VSP150421113B10.2298/VSP150421113B29309104
- 15. Vekic B, Dragojevic-Simic V, Jakovljevic M, Pilipovic F, Simic R, Zivic R, et al. Medical cost of colorectal cancer services in Serbia between 2014 and 2017: National data report. Front Pharmacol. 2019;10:526. DOI: 10.3389/fphar.2019.0052610.3389/fphar.2019.00526653040531156439
- 16. Patel A, Tripathi G, Gopalakrishnan K, Williams N, Arasaradnam RP. Field cancerisation in colorectal cancer: a new frontier or pastures past? World J Gastroenterol. 2015;21(13):3763-72. DOI: 10.3748/wjg.v21. i13.376310.3748/wjg.v21.i13.3763
- 17. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD and Dunnick JK. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis. 2007;28:1851-8. DOI: 10.1093/carcin/ bgm17610.1093/carcin/bgm176
- 18. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:13-21. DOI: 10.1093/annonc/mdu37810.1093/annonc/mdu37825115304
- 19. Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF mutations as prognostic and predictive biomarkers for standard chemotherapy response in metastatic colorectal cancer: A single institutional study. Cells 2020;9(1):219. DOI: 10.3390/cells901021910.3390/cells9010219701663431952366
- 20. Bruera G, Cannita K, Di Giacomo D, Lamy A, FrébourgT, Sabourin JS, et al. Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemo-therapy plus bevacizumab (FIr-B/FOx). BMC Med. 2013;11:59. DOI: 10.1186/1741-7015-11-5910.1186/1741-7015-11-59363586923497191
- 21. Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116(7):923-9. DOI: 10.1038/bjc.2017.3710.1038/bjc.2017.37537914928208157
- 22. Sirisena ND, Deen K, Mandawala DEN, Herath P, Dissanayake VHW. The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka. BMC Research Notes. 2017;10(1):392. DOI: 10.1186/s13104-017-2731-510.1186/s13104-017-2731-5555360628797274
- 23. SadoughA, Afshari M, Rostami F, Berzegari S, Janbabaee G, Tabrizi R, et al. A systematic review and meta-analysis on the prevalence of KRAS gene mutation in samples of colorectal cancer. WCRJ. 2020;7:e1522.
- 24. Jakovljevic K, Malisic E, Cavic M, Krivokuca A, Dobricic J, Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON. 2012;17(3):575-80.
- 25. Jankovic R, Brotto K, MalisicE,Krivokuca A, Cavic M, Jovanovic K, Boljevic I, Tanic M, Radulovic S. KRAS mutations in colorectal cancer patients in Serbia: 5 years experience of central testing. Ann Oncol. 2014;25 (Supplement 2): ii14-ii104.
- 26. Awidi M, Ababneh N, Shomaf M, AlFararjeh F, Owaidi L, Al Khatib M, et al. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan. PloS One. 2019;14(12):e0226473. DOI: 10.1371/journal.pone.022647310.1371/journal.pone.0226473693428831881025
- 27. Korphaisarn K, Pongpaibul A, Roothumnong E,Pong-suktavorn K, Thamlikitkul L, Anekpuritanang T, et al. High frequency of KRAS codon 146 and FBXW7 mutations in Thai patients with stage II-III colon cancer. Asian Pac J CancerPrev. 2019;20(8):2319-26. DOI: 10.31557/APJCP.2019.20.8.231910.31557/APJCP.2019.20.8.2319685281931450901
- 28. Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL. Impact of primary colorectal cancer location on the KRAS status and its prognostic value. BMC Gastroenterol. 2019;19(1):46. DOI: 10.1186/s12876-019-0965-510.1186/s12876-019-0965-5643798530917791
- 29. Bylsma LC, Gillezeau C, GarawinTA,Kelsh MA, Fryzek JP, Sangare L, Lowe KA.Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med. 2020;9(3):1044-57. DOI: 10.1002/cam4.274710.1002/cam4.2747699709531856410
- 30. Baran B, OzupekNM, Tetik NY, Acar E, Bekcioglu O, Baskin Y. Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterology Res. 2018;11:264-73. DOI: 10.14740/ gr1062w10.14740/gr1062w608958730116425
- 31. Dai D, Wang Y, Zhu L, Jin H, Wang X. Prognostic value of KRAS mutation status in colorectal cancer patients: a population-based competing risk analysis. Peer J. 2020;8:e9149. DOI: 10.7717/peerj.914910.7717/peerj.9149727188732547859
- 32. Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages BMC Cancer. 2015;15:340. DOI: 10.1186/ s12885-015-1345-310.1186/s12885-015-1345-3442310725929517
- 33. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. Biochemical and structural analysis of common cancer-associated KRAS mutations. MolCancer Res. 2015;13:1325-35. DOI: 10.1158/1541-7786.MCR-15-020310.1158/1541-7786.MCR-15-020326037647
- 34. Mu-oz-Maldonado C, Zimmer Y, Medová M. A Comparative Analysis of Individual RAS Mutations in Cancer Biology. Front Oncol. 2019;18;9:1088. DOI: 10.3389/fonc.2019.0108810.3389/fonc.2019.01088681320031681616
- 35. Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2016;37(5):6823-30. DOI: 10.1007/s13277-015-4523-710.1007/s13277-015-4523-726662311